Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Gyre Therapeutics closed its acquisition of Cullgen in an all-stock transaction valued at approximately $300 million, creating a fully integrated biopharmaceutical company with operations in the U.S. and China. Dr. Ying Luo, former CEO of Cullgen, was appointed President and Chief Executive Officer of Gyre, while Ping Zhang continues to serve as Chairman of the Board.
Key figures
- Deal Value Usd
- $300 million
- Equity interest in gyre pharmaceuticals
- 69.7%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.